
    
      The study is to investigate the efficacy and safety of apatinib in patients with refractory
      malignant ascites. A total of 120 patients with performance status 0-2 were enrolled in this
      study and 500mg apatinib tablets were administered orally, once daily until disease
      progression or intolerable toxicity or patients withdrawal of consent.
    
  